• Publications
  • Influence
Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
Background Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings.Expand
  • 20
  • 5
  • PDF
Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria
Objective. Data on pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) complex in Nigeria are limited. We investigated species of MTB complex in TB cases from northern Nigeria.Expand
  • 23
  • 3
  • PDF
Antimicrobial use and resistance in Nigeria: situation analysis and recommendations, 2017
Introduction : it is projected that by 2050, 40% of 10 million deaths from Antimicrobial Resistance (AMR) will occur in Africa. Understanding the AMR situation in Nigeria will provide an excellentExpand
  • 16
  • 3
Leprosy situation in Nigeria.
With an annual new case detection of 4000 people, a Grade 2 disability rate of 12%, and nearly 10% child ratio among new cases, leprosy remains a disease of public health importance in Nigeria. FacedExpand
  • 6
  • 2
  • PDF
Clinical profile and containment of the Ebola virus disease outbreak in two large West African cities, Nigeria, July-September 2014.
INTRODUCTION The Ebola virus disease (EVD) outbreak in Nigeria began when an infected diplomat from Liberia arrived in Lagos, the most populous city in Africa, with subsequent transmission to anotherExpand
  • 18
  • 1
  • PDF
The Nigeria Centre for Disease Control
### Summary box Only a few African countries like Ethiopia and Mozambique have long standing National Public Health Institutes (NPHI). However, since the large 2014–2016 Ebola virus disease (EVD)Expand
  • 15
  • 1
Cost-effectiveness of point-of-care digital chest-x-ray in HIV patients with pulmonary mycobacterial infections in Nigeria
BackgroundChest-x-ray is routinely used in the diagnosis of smear negative tuberculosis (TB). This study assesses the incremental cost per true positive test of a point-of-care digital chest-x-ray,Expand
  • 8
  • 1
Testing Pooled Sputum with Xpert MTB/RIF for Diagnosis of Pulmonary Tuberculosis To Increase Affordability in Low-Income Countries
ABSTRACT Tuberculosis (TB) is a global public health problem, with the highest burden occurring in low-income countries. In these countries, the use of more sensitive diagnostics, such as XpertExpand
  • 17
Tuberculosis case detection in Nigeria, the unfinished agenda
Underdetection of TB is a major problem in sub‐Saharan Africa. WHO recommends countries should have at least 1 laboratory per 100 000 population. However, this recommendation is not evidence based.
  • 7
Patients direct costs to undergo TB diagnosis
BackgroundA major impediment to the treatment of TB is a diagnostic process that requires multiple visits. Descriptions of patient costs associated with diagnosis use different protocols and are notExpand
  • 16